After upgrading and transformation, the Beijing Medicine Valley Early Innovative Drug Achievement Transformation Platform, namely, the biomedical public service platform in the Beijing Economic and Technological Development Area (BDA) was recently and officially put into use.

The Beijing Medicine Valley Early Innovative Drug Achievement Transformation Platform [Photo/kfqgw.beijing.gov.cn]

The platform now covers an area of about 6000 square meters and includes 40 laboratories, including labs for analysis and testing, cell investigation, immune cell GMP preparation workshops, biomacromolecule pilot testing, and protein expression and purification. 

The space includes more than 500 sets of equipment such as flow cytometers, bioreactors, carbon dioxide incubators, program cooling devices, biological safety cabinets, liquid nitrogen tanks, and fully automated external preparation equipment.

The Beijing Medicine Valley Early Innovative Drug Achievement Transformation Platform [Photo/kfqgw.beijing.gov.cn]

Since the transformation platform can now carry out such functions as early stage drug achievement transformation and pharmaceutical pilot small testing, and act as an open experiment center and a health food development and biomedicine comprehensive service center, it can offer one-stop services for biomedical professional analysis and testing, GLP, GMP, GCP, achievement incubation and transformation, investment and financing. 

A staff member involved in an experiment [Photo/kfqgw.beijing.gov.cn]

It can also provide professional space, equipment, technology and industrial resource connection services for the research and development of traditional Chinese medicine, macromolecular innovative drugs, and cell therapy technology R&D enterprises.

These laboratories and small and pilot preparation workshops are the hardware part of the biomedical public service platform.

Enterprises only need to focus their limited funds on their own technology; the remaining hardware and personnel investment can be completed on this platform.

Over ten companies such as Shengyi Technology, MagicMed Medical, Jingpiyonghe, and Hua Nuotai Biomedical Technology are transforming their achievements from incubation projects in medical equipment, traditional Chinese medicine, stem cells, and other areas on the platform.